MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$9,169K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of investments
Proceeds from issuance of common...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of investments
Net loss
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-8,185
-10,028
-8,710
-9,353
Stock-based compensation expense
972
1,460
1,400
801
Net accretion of discount on investments
94
81
117
211
Prepaid expenses and other assets
-719
267
-159
-2,513
Accounts payable
-998
-405
795
113
Accrued compensation
482
-1,805
674
545
Accrued liabilities
-103
-285
-653
-249
Other current liabilities
209
-662
1,046
-534
Other non-current liabilities
-
-
170
-
Net cash used in operating activities
-6,998
-12,073
-5,236
-6,375
Purchases of investments
13,660
2,703
8,326
3,890
Maturities of investments
10,000
10,993
15,500
10,000
Net cash provided by investing activities
-3,660
8,290
7,174
6,110
Proceeds from issuance of common stock in the 2026 private placement, net of placement agent fees and other offering costs
143
21,894
-
-
Proceeds from issuance of pre-funded warrants in the 2026 private placement, net of placement agent fees and other offering costs
99
15,372
-
-
Proceeds from issuance of common stock in the atm offerings, net of commissions and offering costs
1,441
-
-
-
Payment of deferred offering costs related to the atm offerings
248
-
-
-
Proceeds from issuance of common stock under the espp
0
39
0
86
Proceeds from exercise of stock options
54
24
0
0
Net cash provided by financing activities
1,489
37,329
0
48
Net increase (decrease) in cash and cash equivalents
-9,169
33,546
1,938
-217
Cash and cash equivalents at the beginning of the period
53,487
19,941
18,003
21,351
Cash and cash equivalents at the end of the period
44,318
53,487
19,941
18,003
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock in the atm...
$1,441K
Proceeds from issuance of
common stock in the 2026...
$143K
Proceeds from issuance of
pre-funded warrants in the...
$99K
Proceeds from exercise of
stock options
$54K
(100.00%↑ Y/Y)
Net cash provided by
financing activities
$1,489K
(2190.77%↑ Y/Y)
Canceled cashflow
$248K
Net increase
(decrease) in cash and cash...
-$9,169K
(-192.85%↓ Y/Y)
Canceled cashflow
$1,489K
Stock-based compensation
expense
$972K
(-75.97%↓ Y/Y)
Prepaid expenses and
other assets
-$719K
(-161.98%↓ Y/Y)
Accrued compensation
$482K
(201.05%↑ Y/Y)
Other current
liabilities
$209K
(382.43%↑ Y/Y)
Maturities of investments
$10,000K
(-79.59%↓ Y/Y)
Payment of deferred
offering costs related to...
$248K
Net cash used in
operating activities
-$6,998K
(61.60%↑ Y/Y)
Net cash provided by
investing activities
-$3,660K
(-124.36%↓ Y/Y)
Canceled cashflow
$2,382K
Canceled cashflow
$10,000K
Net loss
-$8,185K
(52.17%↑ Y/Y)
Purchases of investments
$13,660K
(-59.79%↓ Y/Y)
Accounts payable
-$998K
(17.11%↑ Y/Y)
Accrued liabilities
-$103K
(93.13%↑ Y/Y)
Net accretion of
discount on investments
$94K
(-87.33%↓ Y/Y)
Buy us a coffee
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX)